Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.
Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.
The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children.
V-Con Small Cap Showcase - Companies set to perform and best bargains amidst turbulent market conditions.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts